760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Main Authors: | William Redmond, Brendan Curti, John Cha, Walter Urba, Yoshinobu Koguchi, Brian Piening, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Ipilimumab: Melanoma and beyond
by: Vishal Patel, et al.
Published: (2011-01-01) -
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
by: Wang Wenshi, et al.
Published: (2012-07-01) -
IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2016-12-01) -
Ipilimumab-Induced Neutropenia in Melanoma
by: Makiko Ban-Hoefen MD, et al.
Published: (2016-08-01) -
Use of ipilimumab in the treatment of melanoma
by: Acharya UH, et al.
Published: (2013-08-01)